… was noted in 40 patients, four while receiving erlotinib treatment and 36 after stopping
erlotinib (Appendix Table A1, online only). The median time to recurrence after stopping …

… (EGFR) tyrosine kinase inhibitor erlotinib and the multitargeted antifolate pemetrexed are
registered in the treatment of second-line non-small-cell lung cancer (NSCLC), empirical …

… Erlotinib is currently approved for second-line therapy and … the approval of erlotinib for the
first-line treatment of patients with … at least 1 month of treatment with erlotinib to be assessable. …

… of Cancer Therapy for patients with Lung cancer (FACT-L) scale until disease progression.
An independent review committee of clinicians and radiologists masked to treatment …

… of erlotinib after failure of gefitinib treatment in patients with non-small-cell lung cancer (…
treatment were treated with erlotinib 150 mg/day until disease progression or intolerable toxicity. …

… gene alterations have greatly improved treatment efficacy for non–small cell lung cancer (NSCLC). …
In fact, our low-dose erlotinib therapy could substantially reduce the treatment cost. …

… ) benefit with erlotinib plus bevacizumab compared with erlotinib … (EGFR+) non-small-cell
lung cancer (NSCLC). Here we … assess the impact of erlotinib plus bevacizumab treatment in …

… Patients treated with erlotinib showed better cytologic conversion rate of LMC than those …
NSCLC, erlotinib or gefitinib. The purpose of this study was to assess efficacies of erlotinib and …

… non–small-cell lung cancer (NSCLC). We hypothesized that erlotinib would be efficacious
in … The most common grade 3 adverse events in patients treated with erlotinib were rash (22.3…

… cells to energetic stress induced by treatment with erlotinib. LKB1-deficient cells exhibited
enhanced sensitivity to erlotinib … altered the cellular response to erlotinib treatment, resulting in …